Skip to main content
  • Home
  • Library
  • Read
    • Popular
    • Charts
    • Browse
    • Categories
    • Wikis
    • Glossary
  • Request
  • Activity
  • Leaderboard
  • Help
Our Apps
  • DaoSearch
  • Narratorr
Social
  • Discord
  • Patreon

Recaps

I Can Extract Side Effects
VolumesArcsSummaries

Vol. 1Sanqing’s Rise

Wei Kang transformed Sanqing Pharmaceutical with breakthrough cancer and Alzheimer’s drugs, expanding the company while confronting corporate obstruction and building new businesses. The volume ended with Sanqing launching its Alzheimer’s drug as families worried about whether they could afford it.

  • Wei Kang used the Primary Pharmaceutical System to develop an anti-cancer drug, proved its effectiveness in clinical trials, and attracted international partnership offers while refusing to sell Sanqing or its formula.
  • Wei Kang rejected acquisition offers and favored Pfizer’s licensing terms, asking prospective partners to provide abandoned drug formulas and safety data.
  • Wei Kang signed a $3 billion overseas licensing deal with Pfizer, expanded Sanqing’s businesses, and helped bring its anti-cancer drug to patients despite regulatory obstruction.
  • Wei Kang negotiated affordable domestic insurance prices with Chen Linghui, and the teams began discussing procurement.
  • Wei Kang expanded Sanqing’s facilities and product lines as its cancer drug, hangover medicine, and beauty products gained attention.
  • Wei Kang hired Wenren Long to lead research and help establish an AI Lab for medicinal chemistry.
  • Wei Kang and Chen Yiqing developed Sanqing’s Alzheimer’s drug, whose clinical results drew worldwide attention despite a smear campaign and pressure from Pfizer executives.
  • Sanqing pursued overseas markets independently, announced the drug’s Phase III results and release date, and launched it as families worried about its cost.
Chapters 1–100 Read from Ch. 1

Arc 1Sanqing’s Breakthrough

After discovering he had terminal cancer, Wei Kang used the Primary Pharmaceutical System to create a drug that cured cancer patients and brought Sanqing Pharmaceutical international attention. The arc ended with him weighing licensing offers and seeking multinational companies’ discarded drug formulas to fuel future discoveries.

  • Wei Kang learned he had late-stage liver cancer as Sanqing Pharmaceutical faced heavy losses, then activated the Primary Pharmaceutical System and extracted a cancer-inhibiting effect from a failed drug formula.
  • Wei Kang tested his new anti-cancer drug on himself, and doctors found that his cancer had sharply improved, and he arranged clinical trials with Jian Lianyun and Zhang Bo.
  • Cao Jinmei livestreamed her rapid recovery during the trial, drawing public attention to Sanqing’s drug and prompting a surge of patients and media at the hospital.
  • Wei Kang rejected Xinmei Group’s acquisition offer, raised funds for Sanqing, and announced the company’s anti-cancer and whitening products as the drug advanced through trials.
  • At Sanqing’s launch conference, Wei Kang presented results showing a 100% response and cure rate among 420 patients, defended the data against Dr. Schmitz’s challenge, and attracted partnership offers from major pharmaceutical companies.
  • Wei Kang refused to sell Sanqing or its drug formula and required potential partners to submit toxicity-tested abandoned drug formulas and side-effect data as part of their proposals.
  • Wei Kang rejected Bayer’s acquisition offer and compared licensing proposals, favoring Pfizer’s terms while deciding to negotiate for its extensive catalog of abandoned drug formulas.
Chapters 1–2525 summaries Read

Arc 2Sanqing’s Breakthrough

Wei Kang built Sanqing Pharmaceutical through overseas licensing, new business ventures, and the fight to bring its anti-cancer drug to patients despite corporate and regulatory obstruction. After the drug won public attention and approval, Wei Kang left the arc negotiating an affordable domestic price with medical insurance officials.

  • Wei Kang signed a $3 billion overseas licensing agreement with Pfizer and directed Sanqing to expand production, research, and its future product lines.
  • Sheng Changya warned Wei Kang that Shiseido might acquire the Whitening Drug formula to eliminate a competitor, so Wei Kang rejected Shiseido and Procter & Gamble’s offers and asked Sheng to build a domestic cosmetics brand.
  • Wei Kang developed liver-protection capsules from an abandoned formula and planned new health supplement, cosmetics, and pharmaceutical businesses as Pfizer transferred its initial payment.
  • Jian Guohua recommended Sanqing’s anti-cancer drug to Qi Zhengyang’s family, and the drug stabilized Qi after surgery revealed his cancer had spread to his brain.
  • Merck obstructed the drug’s FDA application, but Qi publicly credited Sanqing with curing his cancer, and Mabus’s campaign led to FDA head Josen’s arrest.
  • Wei Kang announced that Sanqing’s drug had been approved and would launch in China, while Li Senqiang exposed He Shan’s false accusations about Sanqing’s treatment of overseas patients.
  • Wei Kang told the medical insurance negotiation team that Sanqing would price its drug below Keytruda, then offered caps of 200,000 yuan for employee insurance and 150,000 yuan for resident insurance.
  • Chen Linghui accepted Wei Kang’s proposed prices, and the teams began discussing the procurement plan as the hall applauded.
Chapters 26–5025 summaries Read

Arc 3Sanqing’s Expansion

Wei Kang expanded Sanqing through new facilities, recruitment, and a growing beauty business, while the company’s products drew national and international attention. The arc ended with Wei Kang hiring Wenren Long to lead research and help build an AI Lab for medicinal chemistry.

  • Sanqing’s insured cancer drug became accessible in China, while He Shan refused to buy it and died after his cancer spread to his brain.
  • Wei Kang expanded Sanqing’s grounds and launched its hangover medicine, which sold out after Bei Xiaoning and Mabus praised its effects.
  • Wei Kang installed an Intelligent Laboratory System and developed a hair-growth formula, while Sheng Changya built Sanqing Beauty’s Phoenix whitening campaign around Eastern beauty standards.
  • Sanqing Beauty’s Yan Ruyu products sold out, He Rou became their spokesperson, and the brand gained ground against Oulaiya.
  • Wei Kang put Sheng Changya in charge of Sanqing Beauty, gave her 5% of its shares, and approved her hiring a team to expand the product lines.
  • Sanqing recruited widely, raised salaries, and hired researchers and factory workers as its headquarters and laboratories expanded.
  • Wei Kang chose Chen Yiqing and Wenren Long as research candidates, and Wenren Long proposed leading research and creating an AI Lab for medicinal chemistry.
  • Wei Kang hired Wenren Long, who had returned from Eagle Country hoping to serve Chinese people.
Chapters 51–7525 summaries Read

Arc 4The Alzheimer’s Breakthrough

Wei Kang and Chen Yiqing developed Sanqing’s Alzheimer’s drug and proved its promise through clinical trials. After a smear campaign and international pressure, Sanqing pursued overseas markets independently and released the drug, leaving patients and families facing its price.

  • Wei Kang offered Chen Yiqing the R&D director position, and Chen accepted to lead Sanqing’s Alzheimer’s research.
  • Wei Kang used the system to create a γ-secretase inhibitor, and Chen Yiqing, Wenren Long, and Tang Que synthesized and optimized it.
  • Old Man Xie improved during the drug trial, and Sanqing’s researchers published promising results that drew worldwide attention.
  • Pfizer executives encouraged Fox News to accuse Chen Yiqing of stealing research, but the allegations triggered backlash and Sanqing suspended overseas applications.
  • Three Purities released patient data and a recovery documentary, while Fox News apologized after its coverage failed to discredit the drug.
  • Wei Kang prioritized domestic trials, then Sanqing exchanged access to the drug for technology and equipment and chose to manage overseas sales itself.
  • Sanqing’s trials drew patients worldwide, and Amy recovered after learning she had hereditary Alzheimer’s disease.
  • Sanqing announced its Phase III results and release date, then officially launched its Alzheimer’s drug after families anxiously debated its affordability.
Chapters 76–10025 summaries Read
Volume 1 of 7
AboutStatsAPIChangelogStatusContactPrivacyTermsDMCA
© 2026 RandomTranslator·v3.26·RSS